Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies for cancers and autoimmune diseases using its proprietary ARTEMIS® platform, which employs an antibody-T-cell receptor architecture designed to overcome the severe toxicity and high costs associated with conventional CAR-T therapies. The company's lead candidate, EB103, is a CD19-directed T-cell therapy targeting relapsed or refractory B-cell lymphomas, with plans for expansion into solid tumors through collaborations and preclinical programs in autoimmune indications like lupus. Estrella generates value by licensing its ARTEMIS technology platform from Eureka Therapeutics, with revenue potential from development and sales milestones plus royalties on net product sales, while addressing an underserved market of high-risk patients excluded from existing CAR-T therapies due to toxicity concerns and manufacturing complexity.